Wound News and Research

RSS

DuraPrep solution effective against surgical-site infections

3M Health Care today announced the publication of a new independent study “Effects of Preoperative Skin Preparation on Postoperative Wound Infection Rates:

6 Oct 2009

Myocardial and neurological effects of Tβ4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on the results of several important research programs with Thymosin beta 4 (Tβ4) presented at the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

5 Oct 2009

New study reports PRP treatment and its use in sports medicine

Platelet -rich plasma (PRP) is currently used as an alternative treatment method for several common orthopaedic-related sports medicine conditions.

3 Oct 2009

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.

3 Oct 2009

Clinical study data of Thymosin beta 4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on several clinical studies with Thymosin beta 4 (Tβ4) presented the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

3 Oct 2009

Resorbable Orthopedics becomes wholly owned subsidiary of Wound Management Technologies

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today it has closed on its acquisition of Resorbable Orthopedics LLC, a private company with patented technologies including a resorbable bone wax and a delivery system for orthopedic bone void fillers, among others.

1 Oct 2009

Acute therapy and follow-up care of burn disease discussed

Almost three quarters of patients with extensive burns die of the consequences of a severe infection. In the current edition of Deutsches Ärzteblatt International, Timo A. Spanholtz of the Cologne-Merheim Burn Center and his coauthors discuss the acute therapy and follow-up care of burn disease.

1 Oct 2009

Brdt protein in developing sperm cells direct tight re-packaging of sperm DNA

In the quest for speed, olympic swimmers shave themselves or squeeze into high-tech super-suits. In the body, sperm are the only cells that swim and, as speed is crucial to fertility, have developed their own ways to become exceptionally streamlined. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Grenoble, the Institut de Biologie Structurale (IBS) and the Institut Albert Bonniot, both also in Grenoble, have been studying the secrets of speedy sperm.

1 Oct 2009

Study sheds light on why some hospitals have lower mortality than others

A compelling University of Michigan Health System study debunks assumptions about the role of complications in distinguishing good and bad hospitals.

1 Oct 2009

Wound Management Technologies signs sales agreement with Med Pro Associates

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today an agreement with Med Pro Associates of Colorado to serve as a non-exclusive independent sales and marketing representative to solicit sales, obtain orders and provide sales and marketing support for the company's line of products within the U.S.

30 Sep 2009

Share repurchase program announced by Synovis Life Technologies

Synovis Life Technologies, Inc. (Nasdaq: SYNO), a leading biomaterial and surgical products company, today announced that its board of directors has approved a program for the company to repurchase up to 500,000 shares of its common stock.

29 Sep 2009

pSivida reports interim results of human PK study of Iluvien

pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.

29 Sep 2009

Oculus launches Microcyn Skin & Wound HydroGel OTC

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.

29 Sep 2009

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin Irritation tests conducted by WuXi AppTec Inc. (St. Paul, MN) in compliance with Good Laboratory Practice (GLP). Thus, DispersinB® wound gel is considered non-cytotoxic and non-irritant.

28 Sep 2009

$1.3 million fund awarded to WPI for ongoing life sciences research

Researchers at Worcester Polytechnic Institute's (WPI) Life Sciences and Bioengineering Center at Gateway Park have received a total of $1.3 million in new awards from the National Institutes of Health (NIH) and the National Science Foundation (NSF) to fund ongoing research in several areas of the life sciences, including a study of the bacterium that causes tuberculosis, work aimed at using adult stem cells to repair damaged hearts, and a project that seeks to create engineered blood vessels.

28 Sep 2009

$Diabetic patients face increased risk of bone fractures$

Diabetic patients face increased risk of bone fractures

Current research suggests that the inflammatory molecule TNF-α may contribute to delayed bone fracture healing in diabetics. The related report by Alblowi et al, "High Levels of TNF-α Contribute to Accelerated Loss of Cartilage in Diabetic Fracture Healing" appears in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

Wound Management Technologies inks marketing agreement with Pharma Technology International

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today an agreement with Pharma Technology International, LLC (Pharma Tech) to market, distribute and sell the company's wound care products in the Middle East. Pharma Tech is a joint venture between A&Z Pharmaceutical and BioPharma Management Technologies, Inc., a company recently acquired by Wound Management Technologies.

25 Sep 2009

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics, Inc. today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

24 Sep 2009

Enrollment for pSivida's pilot FAVOR clinical study commences

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien in patients with macular edema secondary to retinal vein occlusion.

24 Sep 2009

Stay Fresh textiles technology from Quick-Med

Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today the development of a proprietary Stay Fresh™ technology and that the Company is seeking partners to commercialize this revolutionary new technology in key segments of the textile market.

23 Sep 2009